Robert J. Gould, Director at Fulcrum Therapeutics, Inc. (FULC), sold 142,870 shares at $8.09 ($1.2M) on 2022-06-07, disclosed to the SEC on 2022-06-08.
Open-market sale of $1.2M FULC by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $8.09 | 71,435 | $578K | 50.0% |
| 2 | $8.09 | 71,435 | $578K | 50.0% |
| Total | $8.09 avg | 142,870 | $1.2M | 100% |
| Filing → |
| FULC | SELL | 2026-01-06 | $356K | — | Filing → |
| FULC | SELL | 2025-11-21 | $165K | — | Filing → |
| FULC | SELL | 2023-01-13 | $101K | — | Filing → |